Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

Publication | Closed Access

DOI

414

Citations

References

2021

Year

Xiaotian Zhang, Liang Han, Ziyu Li, Yingwei Xue, Yanong Wang, Zhiwei Zhou, Jiren Yu, Zhaode Bu, Lin Chen, Yian Du,

The Lancet Oncology

D2 GastrectomySurgical OncologyEsophageal CancerGastrointestinal OncologyMedicineSurgeryUpper Gastrointestinal SurgeryAdvanced GastricCancer TreatmentOncologyRadiation OncologyCancer ResearchPhase 3